Steritas LLC. has licensed its STOX® Suite of clinical outcome assessments to argenx, marking a pivotal collaboration in autoimmune disease research. Contract testing labs now have access to validated tools that quantify steroid toxicity, providing vital support in clinical trials and health economics research.
The STOX Suite, derived from the Glucocorticoid Toxicity Index (GTI), offers a comprehensive method to evaluate the safety and efficacy of new steroid-sparing treatments. This partnership highlights the urgent need to address the widespread issue of long-term steroid use and its detrimental effects.
Benefits for Contract Testing Labs
- Streamlined Data Collection: Digital tools enhance efficiency in measuring steroid toxicity.
- Broader Applications: Useful across clinical trials, real-world studies, and health economics research.
- Supports Innovative Therapies: Contributes to the development of steroid-sparing solutions.
- Strengthened Collaborations: Facilitates partnerships with leading pharmaceutical companies.
Steritas and argenx are pioneering a new standard in evaluating and addressing toxicity, providing contract testing labs with powerful tools to lead the charge.
This article is an AI generated summary of a published press release “Steritas announces collaboration with argenx to advance evidence for novel steroid-sparing therapeutics“
